30Nov
30Nov
Regroup Mass Notification Honored with 2021 ‘ASTORS’ Homeland Security Award for Best Mass Notification System
Regroup Mass Notification (http://www.regroup.com) today announced it is the recipient of a 2021 'ASTORS' Homeland Security Award from American Security Today for its mass notification solution. American Security Today's Annual 'ASTORS' Awards is the preeminent U.S. Homeland Security Awards Program, and today in its Sixth Year, continues to recognize industry leaders of Physical and Border Security, Cybersecurity, Emergency Preparedness - Management and Response, Law Enforcement, First Responders, as well as federal, state and municipal government agencies in the acknowledgment of...
25Nov
Parents – Do you Or Your Child Qualify for Public Service Loan Forgiveness?
The Biden Administration's temporary rule changes to the PSLF program are poised to impact hundreds of thousands of borrowers. "Since PSLF launched in 2007, only 16,000 participants have received forgiveness—but that's not for borrowers' lack of trying. Only 2.1 percent of applicants have been approved in the program's lifetime, which critics say is the result of rampant mismanagement, unfair review practices, and an inadequate program design from the start," says Laurel Taylor, CEO, FutureFuel.io, a platform designed to address student...
25Nov
Spotlight: eSight Provides a Unique Solution for Those with Low Sight
Living with low sight presents a lot of challenges, but now there’s a solution. In fact, eSight provides devices that work for people with an array of conditions. Read more >>
24Nov
Stem Cell Agency Board Invests in Therapy Targeting Deadly Blood Cancers
Hematologic malignancies are cancers that affect the blood, bone marrow and lymph nodes and include different forms of leukemia and lymphoma. Current treatments can be effective, but in those patients that do not respond, there are few treatment options. Today, the governing Board of the California Institute for Regenerative Medicine (CIRM) approved investing $4.1 million in a therapy aimed at helping patients who have failed standard therapy. The CIRM Board also approved investing $44,101,935 in 11 projects as part of...
24Nov
Wasabi Technologies Launches London Storage Region as it Ramps Up Global Expansion Plans
Wasabi Technologies, the hot cloud storage company, today announced the opening of a new storage region in London that will expand the availability and speed of services throughout the UK. Building on strong momentum for Wasabi in Europe following a major distribution partnership with Exclusive Networks, one of Europe's largest cybersecurity distributors, the London site also accelerates the company's rapid global expansion with plans to open additional storage regions in the next year. Read more >>
23Nov
New Data Shows Life Sciences Companies Can Reduce Energy and Carbon by Optimizing Ventilation
Aircuity released new data showing that its clients in the life sciences industry are achieving record-setting levels of energy savings and environmental quality in their critical laboratory spaces and across their portfolios. Read more >>
23Nov
Astrocyte Pharmaceuticals Announces Publication in the Journal Stroke of Results Supporting Advancement of AST-004 into in the Clinic
Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, today announced the publication of a manuscript in the peer reviewed journal Stroke entitled: Adenosine A1R/A3R (Adenosine A1 and A3 Receptor) Agonist AST-004 Reduces Brain Infarction in a Nonhuman Primate Model of Stroke. The manuscript describes the results of pre-clinical studies using AST-004, Astrocyte’s lead drug candidate, for the treatment of stroke. Read more >>
21Nov
Akston Biosciences Doses First Subjects in Phase II Clinical Trial in India of Second-Generation COVID-19 Vaccine
Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today that the first of 100 subjects were dosed in an open-label bridging study of AKS-452, its protein subunit COVID-19 vaccine candidate, in India. Read more >>
21Nov